← Evidence map

SynthesisAnnals of hematology2026

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.

Xueying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis. | Socratic